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Anetta Undas1,2 • Jerzy Sadowski1,2 • Grzegorz Kopeć1,2 • Marcin Waligóra2 •
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Abstract Pulmonary endarterectomy (PEA) is a curative
therapeutic approach in patients with chronic thromboem-
bolic pulmonary hypertension (CTEPH). The location-de-
pendent structural differences of thrombotic material found
in pulmonary arteries in CTEPH are poorly investigated.
We present the case of a 47-year-old woman with
antiphospholipid syndrome, diabetes mellitus and abnor-
mal fibrin phenotype, who underwent PEA for CTEPH.
Intravascular material removed bilaterally during PEA
(from lobar, segmental and sub-segmental arteries) has
been studied using light and scanning electron microscopy
(SEM). Light microscopy showed tighter fibrous network
in the portions of intraluminal thrombotic material facing
the vessel wall, which contained collagen and fibrin fibers,
and abundant cells. Cells, evaluated by immunostaining,
were present in the whole removed material. Tissue factor
expression was also observed with the highest values in the
portions of intravascular material facing the vessel wall. In
the main pulmonary arteries, SEM images revealed thick
fibers of fibrous proteins loosly meshed and few erythro-
cytes and platelets between them (both dysmorphic
‘‘wedged’’ and fresh cells were present). In the fibrotic
layers, containing mainly collagen and fibrin, removed
from the lobar/segmental pulmonary arteries we found a
stepwise increase in fiber density with decreasing vessel
calibre, followed by denser fibrous networks composed of
thinner fibers. Elastic fibers in the lobar and segmental arteries
were aligned along the blood flow vector. These findings
demonstrate differences in the structure of endarterectomized
PEA material dependent on the vessel calibre and might
contribute to understanding of CTEPH pathophysiology.
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Introduction
Chronic thromboembolic pulmonary hypertension
(CTEPH) follows almost 4 % of pulmonary embolism (PE)
cases [1]. Pulmonary endarterectomy (PEA) is a treatment
of choice [2]. In case of endogenous thrombolytic potential
failure, thromboembolus can become organized in lungs
through fibroblast invasion, becoming adherent to the
vessel wall [3]. Microscopically, matrix deposition, mixed
cellularity and variable small vessel recanalization is
noticed [4].
Patients with CTEPH are characterized by impaired
fibrinolysis due to alterations in fibrin(ogen) structure,
affecting accessibility to plasmin cleavage sites [5]. Fibrin
clots in CTEPH are lysis-resistant (N-terminal fragments of
the fibrin beta-chain are released) [6]. Also in the setting of
antiphospholipid syndrome (APS), unfavourable fibrin
phenotype and denser clots are observed [7]. Prothrombotic
states and impaired clot dissolution are believed to con-
tribute to CTEPH development in APS [8].
Previously, we reported increasing fibrin content and
fibrin network density with the pulmonary arteries diameter
decrement in acute PE thrombus [9].
Herein we present a case of a 47-year-old woman with
CTEPH, APS and abnormal fibrin properties, who under-
went PEA in our institution. The obtained material was
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studied with multimodal assessment of cellular and acel-
lular contents in light microscopy and scanning electrone
microscopy (SEM).
Case report
A 47-year-old woman (body mass index, 35.2 kg/m2) with
CTEPH, a non-smoker with type 2 diabetes mellitus (DM)
on oral medication (gliclazide ? metformin), gastroin-
testinal reflux disease, parafrenia and a history of deep
venous thrombosis (DVT) in the left lower extremity with
subsequent recurrent PE was admitted to our institution in
December 2014 due to worsening of dyspnea and exertion
intolerance. Last documented episode of DVT followed by
PE occured in July 2013; the treatment with low molecular
weight heparin was then initiated and continued until June
2014, when oral anticoagulation with warfarin was started.
Recommended INR values were 2.0–3.0, but the time
within therapeutic range was 63 %. Due to gradual clinical
detoriation, she underwent evaluation with pulmonary
angiography and computed tomography. While hospital-
ized, the patient presented with exertional dyspnea (4.4
METs on ergospirometry with modified Naughton proto-
col). Transthoracic echocardiogram demonstrated right
ventricular (RV) overload and distention with moderate
tricuspid valve insufficiency, RV systolic pressure
exceeding 85 mmHg and elevated pulmonary pressure with
RV outflow tract acceleration time of 78 ms. Left ven-
tricular systolic function was preserved (left ventricle
ejection fraction was 70 %) and RV systolic function was
mildly impaired (tricuspid annulus systolic excursion was
20 mm). The right heart catheterization revealed mean PA
pressure of 40 mmHg and mean pulmonary artery wedge
pressure of 5 mmHg.
Pulmonary angiogram showed deficient perfusion in
both lungs, with amputated left lower-lobe pulmonary
artery and many ‘‘webs’’ in branches of both pulmonary
arteries (Fig. 1a, b). Contrast-enhanced computed tomog-
raphy (CT) revealed embolic material in the lower-lobe
branches of right and left pulmonary arteries and in their
segmental branches (Fig. 1c). Smaller amounts of embolic
material were also visualized in the segmental branches of
both upper lobar pulmonary arteries, and at the branching
point of the right middle lobar artery. Lower extremities
ultrasound excluded current DVT, and the patient under-
went PEA, which was performed in December 2014.
The PEA was performed with extracorporeal circulation
and temporary circulatory arrest in deep hypothermia. Both
pulmonary arteries were opened. Organized thrombotic
material (Jamieson Type II [10]) was surgically removed
Fig. 1 Pulmonary angiogram, computed tomography and intraoper-
ative images. Pulmonary right (a) and left (b) angiogram showing
deficient perfusion, more pronounced in the right pulmonary artery
(a). Contrast-enhanced computed tomography showing thrombotic
material in lower-lobe branches of right and left pulmonary arteries
(c). Intraoperative picture of the thrombotic material removed from
pulmonary arteries during PEA (d), scale bar 1 cm
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from lobar and segmental branches of the right and left
pulmonary artery (from segments A2, A3, A4–A5, A6–
A10 and A4, A5, A6–A10, respectively) (Fig. 1d). The
patient required prolonged ventilatory support and inten-
sive respiratory rehabilitation during the post-operative
period. During an uneventful 11-month-long follow-up, she
received a warfarin treatment. The clinical work-up
revealed acquired thrombophilia (family history was neg-
ative towards thrombosis) and APS, which was diagnosed
based on the modified APS classification criteria by
Miyakis et al. [11]. Estimation of lupus anticoagulant was
performed using a clot-based assay according to the 2009
recommendations [12]. Anticardiolipin and anti-b2GP-I
antibodies were determined by immunoenzymatic assays
(INOVA Diagnostics, San Diego, USA). Reference ranges
for IgG were up to 15 GPL and 8 SGU, respectively, and
for IgM up to 17 MPL and 10 SMU, respectively. The
diagnosis was reevaluated after 12–16 weeks [13]. The
following auto-immunology workup was non-specific and
did not confirm any other systemic auto-immune disease.
We excluded cancer as a cause of thrombosis. Fibrin
phenotype analysis after 11-months-long follow-up (on
warfarin) was done as previously described [14]. Despite
normal fibrinogen level (2.74 g/l), we found strongly
decreased fibrin clot permeability (Ks = 4.05 ± 0.16
10-9cm2 using a previously described methodology [15]),
as compared with healthy controls from our previous report
(n = 30, Ks = 7.55 [7.00–7.96]) 10-9cm2 [14]).
The resected material from both arteries was divided
into sections to multimodally investigate its morphology
across the specimens (from most proximal through most
distal parts). All sections were investigated with all
modalities. Firstly, the analysis utilizing hematoxylin-eosin
staining performed. It revealed abundant cells influx and
the presence of fibrous tissue in all sections. Immunos-
taining showed the accumulation of collagen and fibrin and
identified the cells as macrophages (anti-CD68?staining)
and fibroblasts, dispersed all over the sections (Fig. 2a).
Coexisting fibrin (Fig. 2b) and collagen (Fig. 2c, d) were
found explicitly on the surface of the intravascular material
facing the vessel wall, forming an uniform layer in all
specimens from small-calibre and large-calibre pulmonary
vessels. Furthermore, we performed a collagen fibers
density measurement, in which the distance between two
adjacent fibres was assessed and expressed as a mean of 15
single measurements ± standard deviation. We observed
an enhanced collagen fibers density (1.426 ± 0.76 lm) in
small-calibre vessels, as compared with the large-calibre
vessels (3.378 ± 1.94 lm) [Fig. 2c, d, respectively, the
depicted differences reflect samples from the small-calibre
(distal) vs. large-calibre (proximal) vessels chosen macro-
scopically during the dissection of the endarterectomized
material]. Tissue factor (TF) staining revealed its presence
within both luminal (facing the vessel lumen) and ablu-
minal (facing the vessel wall) areas, however TF accu-
mulation was prominent within abluminal parts of the
thrombus, corresponding to tighter fibrills network struc-
ture (Fig. 2e).
The thrombotic material was also evaluated using SEM,
as previously described [16]. After washing, the thrombus
was fixed with 2.5 % glutaraldehyde phosphate buffered
saline solution. Specimens were dehydrated, gold coated,
and photographed digitally with a JEOL JSM 5410 (JEOL,
Tokyo, Japan). The SEM images revealed some fresh
thrombotic material in the left PA and fibrous layers as the
effect of chronic thrombosis both in the left and right PA
(Fig. 2f–h). Fibers in the lobar and segmental (right and
left) arteries were aligned along the blood flow vector. The
thrombus structure from the right PA was characterized by
thick fibers and large pores between them. Few erythro-
cytes and platelets (both dysmorphic ‘‘wedged’’ and fresh
cells) were observed between the fibrous layers from large
arteries. In the fibrotic layers removed from the lobar/
segmental (right and left) pulmonary arteries we found a
stepwise increase in fibers density followed by thinner
fibers and smaller pores between them (Fig. 2h). The
elastic fibers layers that coated distal parts of the segmental
(right and left) arteries were much more compressed than
in the proximal parts.
Discussion
This study demonstrates that the structure of intravascular
material in CTEPH is more compact in distal pulmonary
arteries than in proximal ones. We report that within the
intraluminal material in CTEPH, the compaction of fibrin
polymer network and TF expression are increased in the
sections facing the vessel wall.
Wall shear rate and wall shear stress are increased in
smaller arteries, and the final result of thrombosis depends
on interplay between rheodynamics and clot properties
under flow, determined largely by fibrin [17]. Thrombus
degradation efficiency depends on fibrin network charac-
teritics as well [18]. Fibrin clots from CTEPH patients are
lysis resistant, as demonstrated in 2006 by Morris et al. [6].
Recently, Vikerfors et al. demonstrated lower Ks values
and denser fibrin clots in APS patients [7]. Type 2 DM
[19, 20] is also associated with lysis-resistant fibrin. Both
APS and DM are frequently present in CTEPH patiens
[21, 22]. In our patient, impaired fibrin clot characteristics
cannot be explained by an increase in fibrinogen level,
which is an important determinant of Ks, but rather by
alterations in fibrin(ogen) structure. Abnormal fibrin phe-
notype, together with physical factors (different flow
characteristics in vessels of smaller diameter, as compared
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with larger arteries), might determine the creation of dense
and linear network of fibers in vessels of smaller calibre.
Arguably, this can determine the structure of thrombotic
material already early in the course of the disease, and
enable thrombolysis failure despite the anticoagulation [9].
Fibrin not only forms the structural scaffold for throm-
boembolus, but can also activate PA endothelial cells [23]
contributing to vascular remodeling. Fibrin-mediated
increase of interleukin-8 expression facilitates migration of
repair cells along the endothelial cells by interaction with
intracellular adhesion molecule type 1 [24] and macro-
phage-1 antigen [25] receptors, which might partially elu-
cidate fibrin-macrophages collocalization presented by us.
In our intravascular specimens, TF expression was
observed predominantly in the abluminal sections (facing
the vessel wall), and fibrous mesh was denser in those
Fig. 2 Representative
immunostaining and scanning
electron microscopic (SEM)
images. Representative
micorphotgraphs of thrombi
immunostaining showing
a cellular structure of thrombi.
Cells nuclei stained with DAPI
(blue); b fibrin immunostaining
(green), collagen
immunostaining of c small
vessels and d large vessels
(green); e tissue factor
immunostaining (green).
Arrows indicate positive
staining; stars indicate
abluminal section;
a–e magnification 940, scale
bar 50 lm. Representative SEM
images of endarterectomized
material from the right distal
pulmonary artery; f the right
proximal pulmonary artery;
g and distal right segmental
artery; h showing different fiber
compaction; f magnification
9100, scale bar 200 lm.
g–h Magnification 91000; scale
bar 20 lm
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parts. In CTEPH, the endothelial cells adjacent to in situ
thrombi tightly attached to vessel walls were found to
express high level of plasminogen activator inhibitor type 1
[26]. The presence of more compact fibrous network in the
abluminal portions might either elicit or reflect the vascu-
lopathic processes involved in CTEPH. Further investiga-
tion is needed to confirm whether the structure of
intravascular material in CTEPH is uniform among the
patients. The CTEPH development itself, at least in some
cases, is likely connected to abnormal fibrin phenotype,
which under favourable physical conditions has the
potential to produce a lysis-resistant clot.
In conclusion, this report shows that intravascular
material in CTEPH is more dense in small-calibre distal
pulmonary arteries. Fibrin network density and TF
expression are increased close to the vessel wall in vessels
of any calibre. The fibers in the intraluminal material in
CTEPH are aligned along the flow vector in pulmonary
arteries. Further investigation is needed to confirm these
observation in a larger group of CTEPH patients.
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